I-125 Versus Pd-103 for Medium Risk Prostate Cancer

Status unconfirmed · Phase 3

Conditions studied: Prostate Cancer

In brief

hypothesis: the shorter half-life of Pd-103 versus I-125, will increase the rate of tumor eradication. A total of 660 patients with AJC clinical stage T1c-T2a prostatic carcinoma (Gleason grade 7 to 9 and/or PSA 10-20 ng/ml) will be randomized to implantation with I-125 (144 Gy) versus Pd-103 (124 Gy).

Key facts

Study ID

NCT00486499

Run by

VA Puget Sound Health Care System

People needed

660

Starts

2003-03-01

Last updated by the study team

2007-06-14

Who can join

Age: 40 and older, up to 90. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• PSA 4-10 ng/ml
• Gleason score 5 or 6

Where it is running

• Group Health Cooperative — Seattle, Washington, United States (enrolling)
• VA Puget Sound — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.